No Data
No Data
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...
Baird Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $5
Express News | Opregen® (Rg6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (Isscr) 2024 Copenhagen International Symposium
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop
Craig-Hallum Initiates Lineage Cell Therapeutics at Buy With $4 Price Target
Lineage Cell Therapeutics Analyst Ratings